BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Deraphan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Deraphan\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07284472-704@assetmemo.bio
DTSTAMP:20261121T004537Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Deraphan: Phase 2/3 readout est. (NCT07284472)
DESCRIPTION:Deraphan\, phase 2/3\, Alzheimer's Disease.\nStudy: Safety and 
 Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer
 's Disease Dementia\nEstimated primary completion: January 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/deraphan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07284472
URL:https://assetmemo.bio/drug/deraphan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
